132 related articles for article (PubMed ID: 35759796)
1. TGFβ and CIS Inhibition Overcomes NK-cell Suppression to Restore Antitumor Immunity.
Souza-Fonseca-Guimaraes F; Rossi GR; Dagley LF; Foroutan M; McCulloch TR; Yousef J; Park HY; Gunter JH; Beavis PA; Lin CY; Hediyeh-Zadeh S; Camilleri T; Davis MJ; Huntington ND
Cancer Immunol Res; 2022 Sep; 10(9):1047-1054. PubMed ID: 35759796
[TBL] [Abstract][Full Text] [Related]
2. Stimulation of Natural Killer Cell-Mediated Tumor Immunity by an IL15/TGFβ-Neutralizing Fusion Protein.
Ng S; Deng J; Chinnadurai R; Yuan S; Pennati A; Galipeau J
Cancer Res; 2016 Oct; 76(19):5683-5695. PubMed ID: 27488533
[TBL] [Abstract][Full Text] [Related]
3. CIS and TGF-β regulatory pathways influence immunity to bacterial infection.
McCulloch TR; Rossi GR; Schreuder J; Belz GT; Wells TJ; Souza-Fonseca-Guimaraes F
Immunology; 2022 Sep; 167(1):54-63. PubMed ID: 35611558
[TBL] [Abstract][Full Text] [Related]
4. Targeting CISH enhances natural cytotoxicity receptor signaling and reduces NK cell exhaustion to improve solid tumor immunity.
Bernard PL; Delconte R; Pastor S; Laletin V; Costa Da Silva C; Goubard A; Josselin E; Castellano R; Krug A; Vernerey J; Devillier R; Olive D; Verhoeyen E; Vivier E; Huntington ND; Nunes J; Guittard G
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35589278
[TBL] [Abstract][Full Text] [Related]
5. The tumor microenvironment drives NK cell metabolic dysfunction leading to impaired antitumor activity.
Tumino N; Nava Lauson CB; Tiberti S; Besi F; Martini S; Fiore PF; Scodamaglia F; Mingari MC; Moretta L; Manzo T; Vacca P
Int J Cancer; 2023 Apr; 152(8):1698-1706. PubMed ID: 36468179
[TBL] [Abstract][Full Text] [Related]
6. The combination of NK and CD8+T cells with CCL20/IL15-armed oncolytic adenoviruses enhances the growth suppression of TERT-positive tumor cells.
Ye JF; Qi WX; Liu MY; Li Y
Cell Immunol; 2017 Aug; 318():35-41. PubMed ID: 28651743
[TBL] [Abstract][Full Text] [Related]
7. Bifunctional TGF-β trap/IL-15 protein complex elicits potent NK cell and CD8
Liu B; Zhu X; Kong L; Wang M; Spanoudis C; Chaturvedi P; George V; Jiao JA; You L; Egan JO; Echeverri C; Gallo VL; Xing J; Ravelo K; Prendes C; Antolinez J; Denissova J; Muniz GJ; Jeng EK; Rhode PR; Wong HC
Mol Ther; 2021 Oct; 29(10):2949-2962. PubMed ID: 34091051
[TBL] [Abstract][Full Text] [Related]
8. Engineering the TGFβ Receptor to Enhance the Therapeutic Potential of Natural Killer Cells as an Immunotherapy for Neuroblastoma.
Burga RA; Yvon E; Chorvinsky E; Fernandes R; Cruz CRY; Bollard CM
Clin Cancer Res; 2019 Jul; 25(14):4400-4412. PubMed ID: 31010834
[TBL] [Abstract][Full Text] [Related]
9. Human tumour immune evasion via TGF-β blocks NK cell activation but not survival allowing therapeutic restoration of anti-tumour activity.
Wilson EB; El-Jawhari JJ; Neilson AL; Hall GD; Melcher AA; Meade JL; Cook GP
PLoS One; 2011; 6(9):e22842. PubMed ID: 21909397
[TBL] [Abstract][Full Text] [Related]
10. Landscape of innate lymphoid cells in human head and neck cancer reveals divergent NK cell states in the tumor microenvironment.
Moreno-Nieves UY; Tay JK; Saumyaa S; Horowitz NB; Shin JH; Mohammad IA; Luca B; Mundy DC; Gulati GS; Bedi N; Chang S; Chen C; Kaplan MJ; Rosenthal EL; Holsinger FC; Divi V; Baik FM; Sirjani DB; Gentles AJ; Newman AM; Freud AG; Sunwoo JB
Proc Natl Acad Sci U S A; 2021 Jul; 118(28):. PubMed ID: 34244432
[TBL] [Abstract][Full Text] [Related]
11. IL15 Stimulation with TIGIT Blockade Reverses CD155-mediated NK-Cell Dysfunction in Melanoma.
Chauvin JM; Ka M; Pagliano O; Menna C; Ding Q; DeBlasio R; Sanders C; Hou J; Li XY; Ferrone S; Davar D; Kirkwood JM; Johnston RJ; Korman AJ; Smyth MJ; Zarour HM
Clin Cancer Res; 2020 Oct; 26(20):5520-5533. PubMed ID: 32591463
[TBL] [Abstract][Full Text] [Related]
12. High dose CD11c-driven IL15 is sufficient to drive NK cell maturation and anti-tumor activity in a trans-presentation independent manner.
Polansky JK; Bahri R; Divivier M; Duitman EH; Vock C; Goyeneche-Patino DA; Orinska Z; Bulfone-Paus S
Sci Rep; 2016 Jan; 6():19699. PubMed ID: 26822794
[TBL] [Abstract][Full Text] [Related]
13. Human umbilical cord blood-derived mesenchymal stem cells producing IL15 eradicate established pancreatic tumor in syngeneic mice.
Jing W; Chen Y; Lu L; Hu X; Shao C; Zhang Y; Zhou X; Zhou Y; Wu L; Liu R; Fan K; Jin G
Mol Cancer Ther; 2014 Aug; 13(8):2127-37. PubMed ID: 24928851
[TBL] [Abstract][Full Text] [Related]
14. An IL-15 superagonist/IL-15Rα fusion complex protects and rescues NK cell-cytotoxic function from TGF-β1-mediated immunosuppression.
Fujii R; Jochems C; Tritsch SR; Wong HC; Schlom J; Hodge JW
Cancer Immunol Immunother; 2018 Apr; 67(4):675-689. PubMed ID: 29392336
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic blockade of activin-A improves NK cell function and antitumor immunity.
Rautela J; Dagley LF; de Oliveira CC; Schuster IS; Hediyeh-Zadeh S; Delconte RB; Cursons J; Hennessy R; Hutchinson DS; Harrison C; Kita B; Vivier E; Webb AI; Degli-Esposti MA; Davis MJ; Huntington ND; Souza-Fonseca-Guimaraes F
Sci Signal; 2019 Aug; 12(596):. PubMed ID: 31455725
[TBL] [Abstract][Full Text] [Related]
16. Metabolic Reprograming via Deletion of CISH in Human iPSC-Derived NK Cells Promotes In Vivo Persistence and Enhances Anti-tumor Activity.
Zhu H; Blum RH; Bernareggi D; Ask EH; Wu Z; Hoel HJ; Meng Z; Wu C; Guan KL; Malmberg KJ; Kaufman DS
Cell Stem Cell; 2020 Aug; 27(2):224-237.e6. PubMed ID: 32531207
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of MDSC Trafficking with SX-682, a CXCR1/2 Inhibitor, Enhances NK-Cell Immunotherapy in Head and Neck Cancer Models.
Greene S; Robbins Y; Mydlarz WK; Huynh AP; Schmitt NC; Friedman J; Horn LA; Palena C; Schlom J; Maeda DY; Zebala JA; Clavijo PE; Allen C
Clin Cancer Res; 2020 Mar; 26(6):1420-1431. PubMed ID: 31848188
[TBL] [Abstract][Full Text] [Related]
18. Heterodimeric IL-15 delays tumor growth and promotes intratumoral CTL and dendritic cell accumulation by a cytokine network involving XCL1, IFN-γ, CXCL9 and CXCL10.
Bergamaschi C; Pandit H; Nagy BA; Stellas D; Jensen SM; Bear J; Cam M; Valentin A; Fox BA; Felber BK; Pavlakis GN
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461349
[TBL] [Abstract][Full Text] [Related]
19. PRDX-1 Supports the Survival and Antitumor Activity of Primary and CAR-Modified NK Cells under Oxidative Stress.
Klopotowska M; Bajor M; Graczyk-Jarzynka A; Kraft A; Pilch Z; Zhylko A; Firczuk M; Baranowska I; Lazniewski M; Plewczynski D; Goral A; Soroczynska K; Domagala J; Marhelava K; Slusarczyk A; Retecki K; Ramji K; Krawczyk M; Temples MN; Sharma B; Lachota M; Netskar H; Malmberg KJ; Zagozdzon R; Winiarska M
Cancer Immunol Res; 2022 Feb; 10(2):228-244. PubMed ID: 34853030
[TBL] [Abstract][Full Text] [Related]
20. TGF-β inhibits the activation and functions of NK cells by repressing the mTOR pathway.
Viel S; Marçais A; Guimaraes FS; Loftus R; Rabilloud J; Grau M; Degouve S; Djebali S; Sanlaville A; Charrier E; Bienvenu J; Marie JC; Caux C; Marvel J; Town L; Huntington ND; Bartholin L; Finlay D; Smyth MJ; Walzer T
Sci Signal; 2016 Feb; 9(415):ra19. PubMed ID: 26884601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
